AmrytPharma signs European distribution deal for cholesterol drug

Biopharmaceutical company Amryt Pharma has further expanded the route-to-market for Lojuxta, having signed an exclusive distribution agreement across and Central and Eastern Europe with local outfit GryNumber Health.

Amryt's agreement with GryNumber, a healthcare consultancy and distribution company in the region, covers distribution of Lojuxta in Austria, Croatia, the Czech Repblic, Estonia, Finland, Hungary, Latvia, Lithuania, Poland, Slovakia and Slovenia.

Amryt had previously signed distribution deals for Lojuxta, used to treat a rare life-threatening genetic disorder called homozygous familial hypercholesterolemia (HoFH), across Saudi Arabia and Switzerland.

Dr Joe Wiley, chief executive officer of Amryt Pharma, said, "GryNumber Health has a well-established presence in, and significant experience of, the healthcare markets in Central and Eastern Europe and therefore is an ideal partner for us in the region."

"We are delighted to have signed this exclusive distribution agreement as we look to provide access to Lojuxta to patients suffering from HoFH across our licensed territories," he added.

As of 0840 GMT, shares had dipped 0.30% to 19.94p.